Clinical laboratories in Donostia, Gasteiz and Bilbao
RPS 131/24Privacy
Combined pathway

Coagulation studies

Measures coagulation times and parameters such as PT/INR and aPTT, according to the request. It may form part of pre-operative or anticoagulant monitoring.

SampleVenous blood in a correctly filled citrate tube.
FastingFasting is usually not required unless combined with other tests.
Indicative turnaroundTiming depends on the requested test and active pathway; coagulation samples have strict pre-analytical requirements.
PathwayCombined pathway
Available atDonostia · Gasteiz · Bilbo

Why it is performed

  • Assess bleeding or coagulation disorders when clinically indicated.
  • Support pre-operative assessment when the procedure and history justify it.
  • Monitor specific anticoagulants: INR is mainly used for vitamin K antagonists and not as routine measurement for all DOACs.

How it is performed

Blood is collected without unnecessary prolonged tourniquet use and the tube is filled to the mark to preserve the blood/citrate ratio. It is gently mixed and processed or referred within specified time and temperature limits.

Preparation

  • Report the name, dose and time of the last anticoagulant or antiplatelet dose.
  • Do not stop anticoagulants on your own before sampling or surgery.
  • Clotted, underfilled or contaminated samples may need repeating.

How Askabide processes it

Combined pathway

Coagulometric tests such as PT/INR, aPTT and, when requested, fibrinogen or other studies. Askabide will confirm which tests are performed on site and which follow the partner-laboratory pathway.

Part is performed at Askabide and another phase or confirmation is processed externally.

Results and indicative intervals

Intervals vary by method, analyser, reagent, units, age, sex, pregnancy, menstrual-cycle phase and reference population. The valid interval is the one printed on the laboratory report.
Parameter or resultIndicative referenceHow it is interpreted
PTAprox. 11–13,5 sReagent-dependent; INR is often also reported.
INR without anticoagulationAprox. 0,8–1,1The therapeutic target on anticoagulation is set by the clinician and differs from the untreated interval.
aPTTAprox. 25–35 sVaries substantially by instrument and reagent; always use the report’s interval.
FibrinogenAprox. 200–400 mg/dLMay rise with inflammation and vary with pregnancy and method.

Important limitations

  • Intervals are particularly reagent- and analyser-dependent.
  • A normal result does not exclude every bleeding disorder.
  • DOACs can affect some tests unpredictably and may require specific assays in selected situations.
  • Urgent interpretation of a very high INR or active bleeding requires clinical assessment, not a website.
This website provides general information about clinical laboratory tests and diagnostic procedures. It does not replace an individual clinical assessment or the interpretation of the report issued by the laboratory.
Published reference values are indicative and may vary according to the method, equipment, units and individual characteristics.